Circulating testosterone levels and health outcomes in chronic obstructive pulmonary disease: results from ECLIPSE and ERICA
Open Access
- 14 June 2023
- journal article
- research article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 10 (1) , e001601
Abstract
The relationship of circulating testosterone levels with health outcomes in people with chronic obstructive pulmonary disease (COPD) is unknown. Aim To determine whether serum testosterone levels predict hospitalised acute exacerbations of COPD (H-AECOPD), cardiovascular disease outcome, and mortality in people with COPD. Methods Separate analyses were carried out on two observational, multicentre COPD cohorts, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) and Evaluation of the Role of Inflammation in Chronic Airways Disease (ERICA), both of which had serum testosterone measured using a validated liquid chromatography assay at the same laboratory. Data from 1296 male participants in ECLIPSE and 386 male, 239 female participants in ERICA were analysed. All analyses were sex-specific. Multivariate logistic regression was used to determine associations with H-AECOPD during follow-up (3 years ECLIPSE, 4.5 years ERICA), a composite endpoint of cardiovascular hospitalisation and cardiovascular death, and all-cause mortality. Results Mean (SD) testosterone levels were consistent across cohorts; 459 (197) and 455 (200) ng/dL for males in ECLIPSE and ERICA, respectively, and in ERICA females: 28 (56) ng/dL. Testosterone was not associated with H-AECOPD (ECLIPSE: OR: 0.76, p=0.329, ERICA males: OR (95% CI): 1.06 (0.73 to 1.56), p=0.779, ERICA females: OR: 0.77 (0.52 to 1.12), p=0.178) or cardiovascular hospitalisation and death. Testosterone was associated with all-cause mortality in Global Initiative for Obstructive Lung Disease (GOLD) stage 2 male patients only, in ECLIPSE (OR: 0.25, p=0.007) and ERICA (OR: (95% CI): 0.56 (0.32 to 0.95), p=0.030). Conclusions Testosterone levels do not relate to H-AECOPD or cardiovascular outcome in COPD, but are associated with all-cause mortality in GOLD stage 2 COPD male patients, although the clinical significance of this finding is uncertain.Keywords
Funding Information
- Experimental Medicine Training Initiative programme (Clinical Lectureship)
- The NIHR Cambridge BRC (BRC-1215-20014)
- Cambridge BHF Centre of Research Excellence (Non-clinical PhD Studentship)
This publication has 40 references indexed in Scilit:
- Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysisBMJ Open, 2013
- A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: The French 3C cohort studyMaturitas, 2013
- Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2011
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older MenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)European Respiratory Journal, 2008
- Low Serum Testosterone and Mortality in Older MenThe Journal of Clinical Endocrinology & Metabolism, 2008
- The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseasesEuropean Journal of Epidemiology, 2007
- COPD exacerbations: definitions and classificationsEuropean Respiratory Journal, 2003
- SPECIAL REPORT: Report of National Institute on Aging Advisory Panel on Testosterone Replacement in MenThe Journal of Clinical Endocrinology & Metabolism, 2001